DALLAS - Spectral AI, Inc. (NASDAQ:MDAI), a leading artificial intelligence company in medical diagnostics, announced Monday a new contract with the Defense Health Agency (DHA) and the US Army Medical Material Development Activity (USAMMDA).
The contract, valued at over $500,000, supports the development of the DeepView SnapShot® M, a handheld wound imaging system designed to enhance medical care in various settings, including military and home health care.
The DeepView SnapShot® M, part of the DeepView™ Wound Imaging System suite, is aimed at optimizing functionality and size to ensure combat readiness. This initiative is a continuation of Spectral AI's commitment to advancing medical technology, with this latest contract increasing the total non-dilutive funding for the handheld device to over $6 million.
Pete Carlson, CEO of Spectral AI, emphasized the partnership's potential impact on medical care, particularly in battlefield conditions. "We firmly believe that this collaboration will make a profound impact, as the miniaturization of medical devices is essential for introducing innovative medical care to a wider range of clinical settings and patients," Carlson stated.
Spectral AI has garnered significant financial support from the US Government, with total non-dilutive funding exceeding $250 million, including $150 million awarded in the last six months. These funds have been pivotal in advancing the company's AI-driven healthcare innovations, particularly in the field of wound care diagnostics.
The DeepView™ System is designed to provide clinicians with an objective and immediate assessment of a wound's healing potential, which is expected to improve patient outcomes and reduce healthcare costs by providing faster and more accurate treatment insights.
The information is based on a press release statement from Spectral AI.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.